Navidea Biopharmaceuticals
Logotype for Navidea Biopharmaceuticals Inc

Navidea Biopharmaceuticals (NAVB) investor relations material

Navidea Biopharmaceuticals has been delisted

Navidea Biopharmaceuticals EGM 2024 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Navidea Biopharmaceuticals Inc
EGM 2024 summary8 Jul, 2024

Opening remarks and agenda

  • Meeting called to order by the CFO, acting as chairman, and held virtually via webcast.

  • Agenda included in the notice of special meeting and displayed to participants.

Specific resolutions to be voted on

  • Approval of an amendment to allow stockholders to act by written consent.

  • Approval of an amendment to effect a reverse stock split at a ratio of up to 1-for-50,000, with timing and ratio at the board's discretion.

Corporate governance

  • Notice of meeting and shareholder list made available; quorum confirmed.

  • Inspector of Elections appointed and polls opened for voting.

  • Voting procedures clarified for shareholders holding stock in street name.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.
Latest events from Navidea Biopharmaceuticals
    Navidea Biopharmaceuticals
    Cover every name on your watchlist this earnings season.
    Automations, AI chat, and live calls across 16,000+ companies.
    Book demo

    AI chat

    Ask anything. Verify everything.

    Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

    Find what matters

    AI across all first-party IR material. Live calls, transcripts, slides, filings.
    A cited source card from Adobe's CFO alongside a list of forward-looking statements

    Trust every finding

    50m+ first-party documents. Every output traceable to its source.

    Automations

    Zero in on what matters

    Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
    An automation set to trigger on the first published earnings document for GE Aerospace

    Event-triggered research

    Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
    An automation scheduled to run weekly on Mondays at 09:00

    Scheduled research

    Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

    Live audio & transcripts

    Be first

    Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
    A live LVMH Q2 2026 earnings call playing in Quartr

    Live earnings calls

    Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
    A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

    Live transcripts

    Speaker-by-speaker, in real time. Searchable across every live and historical call.

    Quartr MCP connects your AI environment to 17K+ public companies

    Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
    Included with Quartr Pro at no extra cost.Learn more

    Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

    Jamie Ross

    Investment Manager, GAM Investments

    GAM
    GAM

    Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

    Tom O'Hara

    Investment Director

    Ciena
    Ciena

    Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

    Gregg Lampf

    VP of Investor Relations

    Frequently asked questions

    Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing precision immunodiagnostic agents and immunotherapeutics. Its primary technology platform, Manocept, is designed to target the CD206 receptor found on activated macrophages, which plays a key role in diagnosing and treating diseases such as cancer, autoimmune conditions, and inflammatory diseases. The company operates through two main segments: Diagnostic Substances, which include imaging agents, and Therapeutic Development Programs, aimed at therapeutic applications of its platform. Navidea is headquartered in Dublin, Ohio, and its shares are traded on the OTC Markets.